Regeneus picks US manufacturing partner for Kvax
Regeneus (ASX:RGS) has selected a US manufacturing partner for its autologous canine cancer treatment Kvax.
Under the deal, veterinary vaccine manufacturer Hennessy Research will be sent parts of tumours or biopsies from veterinary clinics, manufacture Kvax and ship the vaccine back to the clinics.
“Hennessy Research has a very strong reputation in the animal vaccine field and an impeccable track record with the US veterinary regulators,” said Duncan Thomson, head of Regeneus’s veterinary business unit. “The partnership ... allows us entry into the world’s biggest veterinary market, the US market.”
Regeneus secured approval in November to commercialise Kvax in the US market. The company is preparing to conduct marketing trials in the nation, and Hennessy will produce the immunotherapy for the study.
The Kvax immunotherapy technology was developed at the Bill Walsh Translational Cancer Research Laboratory of the Kolling Institute of Medical Research at Sydney’s Royal North Shore Hospital.
The technology is designed to stimulate the patient’s immune system into recognising cancer cells as foreign and targeting them.
Regeneus has licensed the global veterinary rights to the technology, and also has an option covering human applications.
Regeneus (ASX:RGS) shares were trading 1.12% lower at $0.440 as of around 1 pm on Monday
Immune cell boost could enable lasting vaccine protection
A research team has found a promising new way to enhance the effectiveness of vaccines by tapping...
Genes influence when babies start walking
Genetics accounts for about a quarter of the differences in when children take their first steps,...
Novel glycopeptide antibiotic candidate shows promise
Researchers have discovered a new type of glycopeptide antibiotic known as saarvienin A, found to...
